High Intensity Focused Ultrasound (HIFU) Aesthetics Market

Commission Implementing Regulation (EU) 2022/2346 pulled ultrasound fat-reduction equipment sold without a medical purpose into notified-body conformity assessment, applying from 22 June 2023, and the consequence is a two-speed market for High Intensity Focused Ultrasound (HIFU) aesthetics. The High Intensity Focused Ultrasound (HIFU) Aesthetics market covers professional HIFU systems, their cartridges and transducers, and home-use HIFU devices used to lift, tighten and contour skin without incisions. Douglas Insights sizes it at USD 812.4 million in 2025, built as 12.46 million treatment sessions times USD 65.2 of manufacturer revenue per session, rising to USD 1.68 billion by 2035 at a revenue CAGR of 7.51%. The figures sit inside our medical devices coverage and follow the research methodology used across the catalogue.

Who supplies HIFU aesthetics platforms, and how concentrated is the ultrasound lifting competition?

Three suppliers, Classys, Merz Aesthetics and Jeisys Medical, hold an estimated 36.6% of HIFU aesthetics revenue in 2025, with Classys leading at a 16.1% share on the strength of its Ultraformer and Shurink installed base. The rest is split among dozens of Korean, Chinese and European focused ultrasound makers.

Classys reported revenue of KRW 337 billion for 2025, up 39%, in its 2025 annual report, with consumables at 46% of sales and platforms at 52%. Ultraformer has passed 21,000 cumulative units since its 2014 launch, which the company labels the top global HIFU brand. Douglas Insights puts the HIFU portion at 55% of Classys revenue, or USD 130.5 million after converting USD 237.2 million at KRW 1,420 per dollar.

Merz Aesthetics owns Ultherapy, the micro-focused ultrasound with visualization system. Its release of 5 November 2025 announced a new FDA indication for the anterior arms, posterior arms and abdomen, cited over 3.5 million Ultherapy treatments performed globally and a commercial presence in 90 countries. Douglas Insights estimates Merz at a 13.6% share of HIFU aesthetics revenue, weighted to North America and premium European clinics.

Jeisys Medical sells LinearZ, a single-cartridge HIFU platform with linear and dot modes and adjustable depth, alongside its Density radiofrequency line. Hironic gained Indonesian Ministry of Health certification for New Doublo 2.0, which combines fourth-generation HIFU with radiofrequency. Our model gives Jeisys 6.9% and Hironic 4.1%.

Sofwave Medical competes from the edge of the category with SUPERB, a parallel-beam ultrasound that is not focused HIFU. Its full fiscal 2025 revenue reached USD 87.6 million, up 47%, with recurring revenue at 43%, per its results of 17 March 2026. EDAP TMS, whose Focal One serves urology, sits outside this market.

Which HIFU product type makes the money: systems, cartridges or home-use devices?

Cartridges and transducers lead with 47.3% of 2025 HIFU aesthetics revenue, worth USD 384.3 million. Every session consumes shots on a replaceable ultrasound transducer, while a clinic buys a system once every five to seven years.

Cartridges and transducers reach USD 835.1 million by 2035 at 8.07% a year, since installed systems keep pulling consumables long after the capital sale. Professional HIFU systems hold 44.9%, or USD 364.8 million, because new clinics in Asia and the Gulf still buy first platforms; they grow 6.24% to USD 668.2 million.

Home-use HIFU devices are the smallest line at 7.8% and USD 63.3 million, but the fastest, at 9.83% a year to USD 161.7 million. Low-energy handheld ultrasound units sold through beauty retail extend the treatment between clinic visits, which is why our model grows them faster than clinic hardware.

By application, face and neck lifting carries most sessions, while body tightening and submental contouring take a rising slice after new body indications. By end user, dermatology clinics, medical spas and plastic surgery practices buy almost all professional systems.

Why are clinics booking more HIFU skin-tightening sessions each year?

HIFU aesthetics session volume grows 6.15% a year to 2035, from 12.46 million to 22.63 million sessions, because Asian first-time patients, new body indications, home-use ultrasound and younger and male patients each add sessions. Four drivers explain the volume leg.

First-time patients in Asia contribute 2.34 points. Classys counts 11,000 installed units in Korea and 12,000 elsewhere in Asia, and its 2025 annual report shows a 66% global portion of revenue, up from a domestic base. Korean clinics price a full-face HIFU session low enough to make it a repeat, twice-yearly purchase, and that habit is spreading through Southeast Asia. Overseas Ultraformer sales alone passed 14,000 units, so each new export market adds a fleet that then consumes cartridges for years.

Body indications add 1.52 points. The FDA decision of 13 May 2025 found the Ulthera System PRIME Model 2.1 substantially equivalent under regulation 878.4590, and the arms and abdomen indication Merz announced in November 2025 widened the treatable area per patient. A body session uses three to four times the transducer lines of a brow lift, so each new body indication lifts cartridge pull-through per patient.

Younger and male patients add 1.42 points. The ISAPS Global Survey counted 1,239,306 nonsurgical skin tightening procedures worldwide in 2024, up 38.9% on 2023, while total nonsurgical procedures fell 3.1% to 20,535,686. Skin tightening is gaining share inside a flat nonsurgical pool, and HIFU is the energy source most clinics use for it.

Home-use ultrasound devices add 0.87 points. Douglas Insights counts these as sessions at a lower revenue per session, which is why they raise volume faster than value. A handheld HIFU unit sold at retail runs on a low-energy cartridge and is used weekly or monthly, so one buyer generates 12 to 24 counted sessions a year against two for a typical clinic patient. Retail channels in Japan, Korea and China carry most of these units, and the 9.83% segment growth rate reflects that habit. Together the four drivers sum to 6.15 points, the volume leg of the HIFU aesthetics model.

Price adds 1.28 points a year on top of the 6.15-point volume leg. Newer HIFU platforms with real-time ultrasound imaging, such as Ultherapy PRIME, and multi-depth cartridges sell at higher prices, and Douglas Insights expects revenue per session to climb from USD 65.2 to USD 74.0 by 2035.

What headwinds slow HIFU aesthetics adoption after the EU Annex XVI rules?

Three headwinds take about 1.44 points off HIFU aesthetics growth: EU Annex XVI conformity costs, safety complaints and injectable competition, and grey-market cartridges. Without them the revenue CAGR would sit near 8.95% rather than 7.51%.

European compliance removes 0.48 points. Under Regulation (EU) 2022/2346, a non-medical fat-reduction device already on the EU market can stay there only until 22 June 2028 if its maker runs a clinical investigation with a notified body involved. Smaller HIFU brands without clinical data face withdrawal, and Europe grows only 5.86% a year in our model.

Safety complaints and injectable competition remove 0.61 points. Superficial burns, transient nerve irritation and fat loss from poorly set depths appear in clinic complaints, and botulinum toxin and filler budgets compete for the same patient. Douglas Insights models a 4.9% annual churn of HIFU patients toward injectables.

Grey-market cartridges remove 0.35 points from the price leg. Refilled or third-party transducers sell for a fraction of branded ones in parts of Asia and Latin America, and they cap what manufacturers can charge per shot. Brands answer with chip-locked cartridges, which shifts the fight to enforcement rather than price.

Where do HIFU aesthetics sessions concentrate, and which region grows fastest?

Asia Pacific leads HIFU aesthetics with USD 338.8 million in 2025, 41.7% of the total. Korea, Japan, China and Thailand run high ultrasound session counts at modest prices, and the region reaches USD 755.5 million by 2035 at 8.35% a year.

North America follows at USD 214.5 million, rising to USD 422.0 million at 7.00%; ISAPS counted 356,072 nonsurgical skin tightening procedures in the US alone in 2024, the largest national total. Europe holds USD 156.0 million and reaches USD 275.7 million at 5.86%, slowed by Annex XVI compliance.

Latin America is the wildcard at USD 64.2 million, growing 7.66% to USD 134.3 million: Brazil recorded 60,422 skin tightening procedures and Mexico 34,643, and Classys reports 6,000 installed units in the region. The Middle East and Africa is the fastest region at 8.53%, from USD 38.9 million to USD 88.2 million, as Gulf medical spas add HIFU to injectable menus.

How much do clinics pay for a HIFU system and each ultrasound cartridge?

HIFU aesthetics hardware sells in 2 price tiers. Douglas Insights estimates realised prices of USD 18,000 to USD 35,000 for Korean HIFU systems and USD 60,000 to USD 110,000 for imaging-guided premium platforms, with branded cartridges at USD 350 to USD 1,400 each. Manufacturer revenue averages USD 65.2 per HIFU session.

Patient prices are a different number. A clinic charges several hundred dollars for a full-face HIFU session in Korea and well over a thousand in the United States, but the manufacturer captures only the cartridge cost plus a slice of the system price. Our per-session figure of USD 65.2 spreads system revenue over about 215 sessions per installed system per year.

Pricing splits by imaging. Platforms that show the dermis and the superficial muscular aponeurotic system (SMAS) on screen before each line command a premium of about 2.4 times a blind-fire system, and that premium explains most of the 1.28-point price leg.

Is Korea the reference market for HIFU cartridge economics?

Korea sets HIFU aesthetics economics, with 11,000 Classys units installed there against 3,000 in North America. Korean shot pricing and cartridge refresh cycles become the benchmark that export distributors bring to Asia, Latin America and the Middle East.

Classys sold more than 6,400 Shurink units domestically and over 14,000 Ultraformer units abroad, per its 2025 annual report. A clinic with two HIFU systems and high weekly throughput replaces cartridges every few weeks, and that rhythm explains why consumables reached 46% of Classys revenue.

The lesson for Western suppliers is volume, not margin per shot. Douglas Insights calculates that a Korean clinic runs about 1.6 times the annual HIFU sessions of a comparable US practice, which is why Asia Pacific carries the largest share of cartridge revenue.

How does focused ultrasound compare with radiofrequency and parallel-beam devices for skin lifting?

High intensity focused ultrasound targets the SMAS layer for HIFU aesthetics lifting, which radiofrequency microneedling and parallel-beam ultrasound do not reach directly, so HIFU keeps the lifting claim while rivals compete on comfort and downtime. Douglas Insights puts substitution losses at 0.61 points a year.

Intensity is the dividing line. A HIFU aesthetics transducer concentrates acoustic energy at one focal depth until tissue coagulates, while radiofrequency platforms heat the dermis more broadly and often with less discomfort. Sofwave, with about 2,700 systems sold, markets parallel-beam ultrasound for mid-dermal heating. Many Korean HIFU brands answer by bundling radiofrequency in the same chassis, as Hironic does with New Doublo 2.0.

The comparison matters for the forecast. Each patient lost to a non-focused modality removes cartridge pull-through, so our volume leg already nets out modality switching rather than adding it back as a separate restraint.

What does the HIFU aesthetics scope include, and what is left out?

The HIFU aesthetics scope includes 3 product lines, 4 applications and 3 end-user groups, measured at manufacturer revenue: professional systems, cartridges and transducers, and home-use HIFU devices. Oncologic and urologic HIFU, patient fees and service contracts sit outside.

High intensity here means acoustic energy focused tightly enough to coagulate tissue at a set depth, the mechanism 21 CFR 878.4590 describes, which separates these devices from low-intensity imaging ultrasound. Applications cover face and neck lifting, body tightening and contouring, submental contouring, and intimate rejuvenation. End users are dermatology clinics, medical spas and plastic surgery practices. Channels are direct sales and distributors, plus beauty retail for home-use devices.

Readers tracking the wider category can compare this study with our Medical Aesthetic Devices Market report, which includes lasers, radiofrequency and body-contouring platforms. Imaging transducer supply overlaps with the Color Ultrasound Diagnostic Equipment Market, and home-use HIFU sales sit next to the Cosmetics Market in retail.

How do FDA regulation and EU rules classify a HIFU aesthetics device?

US regulation treats HIFU aesthetics devices as Class II focused ultrasound stimulator systems under 21 CFR 878.4590, cleared through 510(k). In the EU, non-medical fat-reduction ultrasound falls under Annex XVI common specifications applying from 22 June 2023.

The FDA record for K250418 lists product code OHV and a substantially equivalent decision for the Ulthera System PRIME Model 2.1. Special controls require a guidance-defined set of performance and safety tests, so new US entrants need bench and clinical data before the first sale.

The EU text of Regulation (EU) 2022/2346 sets dated milestones for devices kept on the market during a clinical investigation: a started investigation from 23 December 2024 and a signed notified-body agreement from 23 June 2026. Annex V names ultrasound among the mechanisms that devices to reduce, remove or destroy adipose tissue must address in risk management.

What if HIFU session growth slows or speeds up before 2035?

HIFU aesthetics revenue reaches USD 1.68 billion in 2035 in the base case. A slower path with 4.05% volume and 0.62% price growth ends near USD 1.29 billion, and a faster path with 8.10% volume and 1.74% price reaches USD 2.10 billion.

A single extra point of annual HIFU session growth adds about USD 164.8 million to the 2035 value, holding price at 1.28 points. The slower case assumes the EU deadline of 22 June 2028 removes more brands than expected and injectables keep taking patients. The faster case assumes body indications like the November 2025 Ultherapy PRIME body indication spread across Korean platforms.

Published forecasts for the wider HIFU and HIFU aesthetics categories run from about 5.4% to 9.6% a year, and our 7.51% sits near the middle. We are below the top estimate because we net out grey-market cartridges and modality switching.

Douglas Exclusive: the HIFU Cartridge Pull-Through Index

The HIFU Cartridge Pull-Through Index is a Douglas Insights model of HIFU aesthetics consumables, built from 14 inputs: 9 sourced figures from company filings and the ISAPS survey, and 5 regional throughput assumptions. It divides annual cartridge and transducer revenue by annual system revenue in each region.

The global HIFU ultrasound index reads 1.05, meaning USD 384.3 million of cartridge revenue against USD 364.8 million of system revenue. Our finding: once a region passes an index of about 1.0, consumables grow faster than hardware, which is why we expect the Middle East and Africa index to rise as its fleet matures.

What methodology turns 12.46 million HIFU sessions into the 2025 value?

Douglas Insights reckons 2025 at 12.46 million HIFU aesthetics sessions times USD 65.2 per session, which equals USD 812.4 million, built across 31 countries and 46 data points. Sessions come from an estimated 58,000 active professional systems running about 215 sessions a year.

Volume grows 6.15% and price 1.28% a year, giving 22.63 million sessions at USD 74.0 in 2035 and a revenue CAGR of 7.51%. Region rows sum to the global figure in 2025 and 2035 within USD 0.1 million.

Cross-checks: Classys HIFU revenue at USD 130.5 million implies a 16.1% share, consistent with its 21,000-unit Ultraformer base inside our 58,000 active systems, a 36.2% fleet share once retired units are removed. ISAPS skin tightening counts cover member surgeons only and capture under 12% of our session total, which matches the survey gap in Korea and China.

Sources

1. EUR-Lex, Publications Office of the European Union Commission Implementing Regulation (EU) 2022/2346, common specifications for Annex XVI products (2022)
2. US Food and Drug Administration 510(k) K250418, Ulthera System PRIME Model 2.1 (2025)
3. eCFR 21 CFR 878.4590 Focused ultrasound stimulator system for aesthetic use (2026)
4. Merz Aesthetics Merz Aesthetics announces new arms and abdomen indication for Ultherapy PRIME (2025)
5. Classys Inc. Classys Annual Report 2025 (2026)
6. Sofwave Medical Sofwave Medical full year 2025 financial results (2026)
7. ISAPS ISAPS International Survey on Aesthetic/Cosmetic Procedures 2024 (2025)
8. Jeisys Medical Jeisys Medical product overview (LinearZ) (2026)